Norcantharidin ameliorates estrogen deficient-mediated bone loss by attenuating the activation of extracellular signal-regulated kinase/ROS/NLRP3 inflammasome signaling

Guang Yang; Guang Yang; Guang Yang; Guang Yang; Huikang Xu; Minjun Yao; Minjun Yao; Minjun Yao; Minjun Yao; Shigui Yan; Shigui Yan; Shigui Yan; Shigui Yan; Mengrui Wu; Chenhe Zhou; Chenhe Zhou; Chenhe Zhou; Chenhe Zhou

doi:10.3389/fphar.2022.1019478

Frontiers in Pharmacology (Nov 2022)

Norcantharidin ameliorates estrogen deficient-mediated bone loss by attenuating the activation of extracellular signal-regulated kinase/ROS/NLRP3 inflammasome signaling

Guang Yang,
Guang Yang,
Guang Yang,
Guang Yang,
Huikang Xu,
Minjun Yao,
Minjun Yao,
Minjun Yao,
Minjun Yao,
Shigui Yan,
Shigui Yan,
Shigui Yan,
Shigui Yan,
Mengrui Wu,
Chenhe Zhou,
Chenhe Zhou,
Chenhe Zhou,
Chenhe Zhou

Affiliations

Guang Yang: Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang, China
Guang Yang: Orthopedics Research Institute of Zhejiang University, Hangzhou City, Zhejiang, China
Guang Yang: Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou City, Zhejiang, China
Guang Yang: Clinical Research Center of Motor System Disease of Zhejiang Province, Hangzhou City, China
Huikang Xu: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Minjun Yao: Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang, China
Minjun Yao: Orthopedics Research Institute of Zhejiang University, Hangzhou City, Zhejiang, China
Minjun Yao: Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou City, Zhejiang, China
Minjun Yao: Clinical Research Center of Motor System Disease of Zhejiang Province, Hangzhou City, China
Shigui Yan: Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang, China
Shigui Yan: Orthopedics Research Institute of Zhejiang University, Hangzhou City, Zhejiang, China
Shigui Yan: Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou City, Zhejiang, China
Shigui Yan: Clinical Research Center of Motor System Disease of Zhejiang Province, Hangzhou City, China
Mengrui Wu: Department of Cell and Developmental Biology, College of Life Sciences, Zhejiang University, Hangzhou, China
Chenhe Zhou: Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang, China
Chenhe Zhou: Orthopedics Research Institute of Zhejiang University, Hangzhou City, Zhejiang, China
Chenhe Zhou: Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou City, Zhejiang, China
Chenhe Zhou: Clinical Research Center of Motor System Disease of Zhejiang Province, Hangzhou City, China

DOI: https://doi.org/10.3389/fphar.2022.1019478
Journal volume & issue: Vol. 13

Abstract

Read online

Osteoporosis, characterized by reduced bone mass, aberrant bone architecture, and elevated bone fragility, is driven by a disruption of bone homeostasis between bone resorption and bone formation. However, up to now, no drugs are perfect for osteoporosis treatment due to different defects. In this study, we demonstrated that norcantharidin (NCTD) could inhibit osteoclast formation and bone resorption by attenuating the ERK, ROS and NLRP3 inflammasomes pathways in vitro. Moreover, our in vivo study further confirms its preventive effects on estrogen-deficiency bone loss by inhibiting osteoclast formation and functions. Therefore, we could conclude that NCTD might be a potential candidates for the prevention and treatment of osteoporosis.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords